Chemotherapy has been a gold standard for treatment of breast cancer and often over-treats women who may not need this aggressive treatment to treat their breast cancer.  Dr. Sparano serves as the study chair for the TAILORx clinical trial sponsored by National Cancer Institute, the first clinical trial integrating a mulitparameter gene expression assay in clinical decision making for adjuvant therapy with early stage ER-positive, HER2 negative breast cancer.  The results will eliminate the use of chemotherapy for thousands of women.